Open for inclusion

Dose-escalation Study of LTX-315 in Patients With a Transdermally Accessible Tumour

Cancer type: Multiple diagnosis

Phase: I/II

Principal Investigator: Brunsvig Paal

Country: NO

Keywords: Norway, Oslo University Hospital

Status: Inclusion completed

Link to Clinicaltrials.gov: http://www.clinicaltrials.gov/ct2/show/NCT01058616?term=C08-315-01&rank=1